Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
t(11;14) and <CR pre-ASCT predict MRD+ post-ASCT, links to inferior PFS and OS; adverse effect of high-risk cytogenetics partially mitigated by MRD-negativity; higher residual clonal PC burden if MRD+ assoc w/ inferior PFS.”
Title: Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma
Authors: Abiola Bolarinwa, Saurabh S. Zanwar, Nadine Abdallah, Madhu Nagaraj, Sukriti Seth, Francis K. Buadi, Suzanne R. Hayman, Morie A. Gertz, Angela Dispenzieri, Eli Muchtar, Prashant Kapoor, Wilson I. Gonsalves, Taxiarchis V. Kourelis, David Dingli, Rahma Warsame, Nelson Leung, Joselle Cook, Moritz Binder, Yi Lin, Yi Lisa Hwa, Michelle Genevieve Rogers, Miriam A. Hobbs, Amie L. Fonder, Dragan Jevremovic, S. Vincent Rajkumar, Shaji K. Kumar
You can read the Full Article on Blood Advances.
You can find other articles featuring Robert Orlowski on OncoDaily.
